Danaher Corp (DHR)
215.01
0.00 (0.00%)
Danaher Corporation is a global science and technology company that designs, manufactures, and markets a diverse range of industrial and healthcare products and solutions
The company's operations are organized into several segments, including life sciences, diagnostics, dental, and environmental and applied solutions. Danaher focuses on advancing vital sciences and technologies through innovative products and services that enhance the quality of life. With a commitment to customer satisfaction, the company leverages its extensive expertise in engineering and manufacturing to deliver reliable and efficient solutions across various industries, helping to drive improved outcomes in healthcare, environmental monitoring, and industrial processes.
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 3, 2025
![](https://cdn.benzinga.com/files/images/story/2025/02/03/FedEx-Corp-.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · February 3, 2025
![](https://news-assets.stockstory.org/cover-images/danaher-corporation-cover-image-447c930dbb9f_2025-01-29-052734_okyg.jpeg)
Diversified science and technology company Danaher (NYSEDHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.1% year on year to $6.54 billion. Its non-GAAP profit of $2.14 per share was 1.3% below analysts’ consensus estimates.
Via StockStory · January 31, 2025
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 30, 2025
![](https://cdn.pixabay.com/photo/2017/08/30/07/56/money-2696228_960_720.jpg)
Total earnings for the 112 S&P 500 companies that have reported results are up +10.8% from the same period last year on +5.5% higher revenues, with 80.4% beating EPS estimates and 68.8% beating revenue estimates.
Via Talk Markets · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/30/West-Bangal--India---April-20--2022--Dan.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 30, 2025
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 15, 2025
![](https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp)
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Via Chartmill · January 29, 2025
![](https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp)
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.
Via Chartmill · January 29, 2025
![](https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp)
Curious about the S&P500 stocks that are gapping on Wednesday? Explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · January 29, 2025
![](https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp)
Pre-market stock analysis of S&P500 stocks on 2025-01-29: top gainers and losers in today's session.
Via Chartmill · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 2, 2025
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · December 24, 2024
![](https://cdn.benzinga.com/files/images/story/2025/01/29/Jerome-Powell.png?width=1200&height=800&fit=crop)
Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET.
Via Benzinga · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/29/Movers-Stocks.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/29/West-Bangal--India---April-20--2022--Dan.jpeg?width=1200&height=800&fit=crop)
Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in biotechnology and life sciences.
Via Benzinga · January 29, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/28/Bitcoins-Reserve-Asset-Appeal-Increased-.jpeg?width=1200&height=800&fit=crop)
Cramer comments on Danaher, Coterra, BlackRock and Digital Realty. As for Grail, "Just great science, but it is parabolic," he adds.
Via Benzinga · January 28, 2025
![](https://g.foolcdn.com/editorial/images/805259/gettyimages-1471299072.jpg)
The object is to buy low and sell high.
Via The Motley Fool · January 25, 2025
![](https://cdn.benzinga.com/files/images/story/2025/01/24/Stethoscope-Laying-On-Medicine-White-Pil.jpeg?width=1200&height=800&fit=crop)
Goldman Sachs predicts a gradual recovery for Life Sciences Tools in 2025, with bioprocessing gaining traction and improved investor sentiment likely.
Via Benzinga · January 24, 2025
![](https://cdn.benzinga.com/files/images/story/2024/12/20/investor-charts-ai2.png?width=1200&height=800&fit=crop)
Dan S. Loeb, founder of Third Point, a $7B hedge fund, is known for bold activist strategies that drive transformation in global companies.
Via Benzinga · December 20, 2024
![](https://cdn.benzinga.com/files/images/story/2024/12/13/Stock-Whisper-Index-Logo-6-copy.jpeg?width=1200&height=800&fit=crop)
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and the reasons why the stocks may be drawing attention.
Via Benzinga · December 13, 2024